Patricia Villar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Patricia Villar has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Laura Gutiérrez
Platelet Research Lab, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain
2 shared publications Andrea Acebes-Huerta
Platelet Research Lab, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain (Villar and Drs Acebes-Huerta and Gutiérrez)
1 shared publication- Andrea Acebes-Huerta
Platelet Research Lab, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain
1 shared publication Carmen Rodríguez-Jiménez
Department of Genetics of Metabolic Diseases, Institute of Medical and Molecular Genetics (INGEMM), Hospital Universitario La Paz, IdiPAZ, Madrid, Spain (Drs Rodríguez-Jiménez and Rodríguez-Nóvoa)
1 shared publication- Diego Gómez-Coronado
Servicio de Bioquímica-Investigación, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034, Madrid, Spain
1 shared publication - Gema de la Peña
Department of Biochemistry-Research, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain (Drs Gómez-Coronado, de la Peña, Martínez-Botas, and Lasunción)
1 shared publication
Latest Publications
- Open Access
- 15 December 2025
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (2) , 411-427
A novel ABCA1 variant associated with impaired platelet production contributing to thrombocytopenia in a family with Tangier disease
- 15 December 2025
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (2) , 411-427
Open AccessA novel ABCA1 variant associated with impaired platelet production contributing to thrombocytopenia in a family with Tangier disease
- Open Access
- 7 June 2023
- Published by Taylor & Francis in Platelets
- Vol. 34 (1) , 2220415
Proteomics-wise, how similar are mouse and human platelets?
The field of proteomics and its application to platelet biology, is rapidly and promisingly developing. Platelets (and megakaryocytes) are postulated as biosensors of health and disease, and their proteome poses as a tool to identify the specific health-disease hallmarks. Furthermore, the clinical management of certain pathologies where platelets are active players demands the development of alternative treatments, such is the case in patients where the balance thrombosis-bleeding is compromised, and a proteomics approach might aid at the identification of novel targets. Hereby, the mouse and human platelet proteomes and secretomes from public databases are compared, which shows that human and mouse platelets share a highly conserved proteome, considering identified proteins, and most importantly, their relative abundance. These supports, also interspecies wise, the use of the proteomics tool in the field, substantiated by a growing number of clinically relevant studies in humans or preclinical models. While the study of platelets through proteomics seems accessible and direct (i.e. noninvasive blood sampling, enucleated), there are some points of concern regarding the quality control of samples for such proteomics studies. Importantly, the quality of the generated data is improving over the years, which will allow cross-study comparisons. In parallel, the application of proteomics to the megakaryocyte compartment has a promising but long journey ahead. We foresee and encourage the application of platelet proteomics for diagnostic/prognostic purposes even beyond hematopoiesis and transfusion medicine, and as a tool that will procure the improvement of current therapies and the development of alternative treatment options.
- 7 June 2023
- Published by Taylor & Francis in Platelets
- Vol. 34 (1) , 2220415
Open AccessProteomics-wise, how similar are mouse and human platelets?
The field of proteomics and its application to platelet biology, is rapidly and promisingly developing. Platelets (and megakaryocytes) are postulated as biosensors of health and disease, and their proteome poses as a tool to identify the specific health-disease hallmarks. Furthermore, the clinical management of certain pathologies where platelets are active players demands the development of alternative treatments, such is the case in patients where the balance thrombosis-bleeding is compromised, and a proteomics approach might aid at the identification of novel targets. Hereby, the mouse and human platelet proteomes and secretomes from public databases are compared, which shows that human and mouse platelets share a highly conserved proteome, considering identified proteins, and most importantly, their relative abundance. These supports, also interspecies wise, the use of the proteomics tool in the field, substantiated by a growing number of clinically relevant studies in humans or preclinical models. While the study of platelets through proteomics seems accessible and direct (i.e. noninvasive blood sampling, enucleated), there are some points of concern regarding the quality control of samples for such proteomics studies. Importantly, the quality of the generated data is improving over the years, which will allow cross-study comparisons. In parallel, the application of proteomics to the megakaryocyte compartment has a promising but long journey ahead. We foresee and encourage the application of platelet proteomics for diagnostic/prognostic purposes even beyond hematopoiesis and transfusion medicine, and as a tool that will procure the improvement of current therapies and the development of alternative treatment options.